Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT05692635Phase 2Recruiting
Phase 2, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Wake Forest University Health Sciences. Primary endpoint: Change in Central Nervous System Symptoms at 26 months. Started Aug 2023; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT05692635.